CoChat

Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity

Open access

The DOI matches its Crossref record; 68 of the 71 references it cites were found in a registry or an index.

Abstract

Recent genetic evidence supports a link between microglia and the complement system in Alzheimer's disease (AD). In this study, we uncovered a novel role for the microglial complement receptor 3 (CR3) in the regulation of soluble β-amyloid (Aβ) clearance independent of phagocytosis. Unexpectedly, ablation of CR3 in human amyloid precursor protein-transgenic mice results in decreased, rather than increased, Aβ accumulation. In line with these findings, cultured microglia lacking CR3 are more efficient than wild-type cells at degrading extracellular Aβ by secreting enzymatic factors, including tissue plasminogen activator. Furthermore, a small molecule modulator of CR3 reduces soluble Aβ levels and Aβ half-life in brain interstitial fluid (ISF), as measured by in vivo microdialysis. These results suggest that CR3 limits Aβ clearance from the ISF, illustrating a novel role for CR3 and microglia in brain Aβ metabolism and defining a potential new therapeutic target in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20162011

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Lack of CR3 results in reduced plaque deposition in APP transgenic mice while leaving APP expression and processing unaffected. (A–D) Aβ staining in cortex (A) and hippocampus (B) of APP and APP/CR3−/− mice and quantification of Aβ immunoreactivity in cortex (C) and hippocampus (D). 12-mo-old mice were used. n = 8–9 mice per group and 6 sections per mouse. *, P < 0.05. Bars, 200 µm. (E and G) Western blots of cortical (E) and hippocampal (G) lysates showing full-length APP (flAPP) and C99 and C83 cleavage products, as well as β-actin and neuron-specific enolase (NSE) loading controls. (F and H) Quantification of Western blots in cortex (F) and hippocampus (H). (E–H) 3-mo-old male and female mice were used. n = 5 mice per group. Unpaired Student’s t test was used. All values are mean ± SEM.
Figure 1. Lack of CR3 results in reduced plaque deposition in APP transgenic mice while leaving APP expression and processing unaffected. (A–D) Aβ staining in cortex (A) and hippocampus (B) of APP and APP/CR3−/− mice and quantification of Aβ immunoreactivity in cortex (C) and hippocampus (D). 12-mo-old mice were used. n = 8–9 mice per group and 6 sections per mouse. *, P < 0.05. Bars, 200 µm. (E and G) Western blots of cortical (E) and hippocampal (G) lysates showing full-length APP (flAPP) and C99 and C83 cleavage products, as well as β-actin and neuron-specific enolase (NSE) loading controls. (F and H) Quantification of Western blots in cortex (F) and hippocampus (H). (E–H) 3-mo-old male and female mice were used. n = 5 mice per group. Unpaired Student’s t test was used. All values are mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 2. CR3 deficiency leads to reduced phagocytic activity and increased Aβ degradation in vitro. (A and B) Western blot (A) and flow cytometric quantification (B) of CD11b expression in CR3kd and control BV2 cell lines. (B) n = 2 replicates. (C and D) Quantification of baseline phagocytosis activity (C) and phagocytosis efficiency (D) in control and CR3kd BV2 cells. (E) Schematic of Aβ degradation assay. (F and G) Cell-based (F) and cell-free (G) Aβ degradation assays of control and CR3kd cells were quantified. (H and I) Aβ degradation using primary adult microglia. (J and K) Aβ staining in hippocampus of mice stereotactically injected with Aβ42 (J) and quantification of residual immunoreactivity (K). 3–4-mo-old male and female mice were used. n = 9 per group. Bar, 200 µm. (C, D, and F–I) Representative graphs of three to five independent experiments are shown. Student’s t test (B, C, H, and K), two-way ANOVA and Sidak’s posthoc test (D), or one-way ANOVA with Tukey’s posthoc test (F, G, and I) were used. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. All values are mean ± SEM.
Figure 2. CR3 deficiency leads to reduced phagocytic activity and increased Aβ degradation in vitro. (A and B) Western blot (A) and flow cytometric quantification (B) of CD11b expression in CR3kd and control BV2 cell lines. (B) n = 2 replicates. (C and D) Quantification of baseline phagocytosis activity (C) and phagocytosis efficiency (D) in control and CR3kd BV2 cells. (E) Schematic of Aβ degradation assay. (F and G) Cell-based (F) and cell-free (G) Aβ degradation assays of control and CR3kd cells were quantified. (H and I) Aβ degradation using primary adult microglia. (J and K) Aβ staining in hippocampus of mice stereotactically injected with Aβ42 (J) and quantification of residual immunoreactivity (K). 3–4-mo-old male and female mice were used. n = 9 per group. Bar, 200 µm. (C, D, and F–I) Representative graphs of three to five independent experiments are shown. Student’s t test (B, C, H, and K), two-way ANOVA and Sidak’s posthoc test (D), or one-way ANOVA with Tukey’s posthoc test (F, G, and I) were used. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. All values are mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 3. CR3-deficient cells and mice display increased tPA activity. (A) Ratio of Aβ measured in conditioned medium from CR3kd versus control BV2 cells after addition of proteinase inhibitors. A representative graph of two independent experiments is shown. PI, protease inhibitor; PI w/o, protease inhibitor cocktail lacking EDTA. (B and C) qPCR analysis of mRNA from adult primary microglia, normalized to GAPDH. Microglia were from n = 7 individual mice. IDE, insulin-degrading enzyme; NEP, neprilysin. (D) Active tPA measurement in conditioned medium from control and CR3kd cells. n = 2 independent experiments. (E and F) Representative image of in situ zymography in the hippocampus (E) and quantification of the lysed area (F). n = 5–6 mice. All mice were 3–4-mo-old males and females. Bar, 500 µm. (G) Aβ degradation assay in control and CRkd cells transfected with control siRNA or tPA siRNA. (H) Knockdown efficiency was quantified by qPCR. Data are combined from two independent experiments. One-way ANOVA with Dunnett’s posthoc test and significance relative to vehicle (A), unpaired Student’s t test (B, C, D, and F), or one-way ANOVA with Tukey’s posthoc test (G and H) were used. *, P < 0.05; **, P < 0.01; ***, P < 0.001. All values are mean ± SEM.
Figure 3. CR3-deficient cells and mice display increased tPA activity. (A) Ratio of Aβ measured in conditioned medium from CR3kd versus control BV2 cells after addition of proteinase inhibitors. A representative graph of two independent experiments is shown. PI, protease inhibitor; PI w/o, protease inhibitor cocktail lacking EDTA. (B and C) qPCR analysis of mRNA from adult primary microglia, normalized to GAPDH. Microglia were from n = 7 individual mice. IDE, insulin-degrading enzyme; NEP, neprilysin. (D) Active tPA measurement in conditioned medium from control and CR3kd cells. n = 2 independent experiments. (E and F) Representative image of in situ zymography in the hippocampus (E) and quantification of the lysed area (F). n = 5–6 mice. All mice were 3–4-mo-old males and females. Bar, 500 µm. (G) Aβ degradation assay in control and CRkd cells transfected with control siRNA or tPA siRNA. (H) Knockdown efficiency was quantified by qPCR. Data are combined from two independent experiments. One-way ANOVA with Dunnett’s posthoc test and significance relative to vehicle (A), unpaired Student’s t test (B, C, D, and F), or one-way ANOVA with Tukey’s posthoc test (G and H) were used. *, P < 0.05; **, P < 0.01; ***, P < 0.001. All values are mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 4. The small molecule modulator LA-1 enhances Aβ degradation in vitro and lowers Aβ levels in vivo. (A and B) Quantification of cell-based Aβ degradation assay with LA-1 treatment in BV2 cells (A) and LA-1 treatment in control and CR3kd cell lines (B). Representative graphs of two to three experiments are shown. (C) Aβ levels in guanidine-extracted fraction in APP mice after LA-1 treatment. n = 8–9 mice, male and female. CX cortex, HC hippocampus. (D) Mass spectrometry quantification of brain levels of LA-1 after single injection. n = 3 per time point, all male mice. (E and F) qPCR analysis of mRNA from primary microglia. n = 5 individual mice, male and female. The dashed line shows the detection limit. (C–F) All mice were 3–4 mo old. One-way ANOVA and Tukey’s posthoc test (A), two-way ANOVA and Bonferroni posthoc test (B), or unpaired Student’s t test (C, E, and F) was used. *, P < 0.05; **, P < 0.01; ***, P < 0.001. All values are mean ± SEM.
Figure 4. The small molecule modulator LA-1 enhances Aβ degradation in vitro and lowers Aβ levels in vivo. (A and B) Quantification of cell-based Aβ degradation assay with LA-1 treatment in BV2 cells (A) and LA-1 treatment in control and CR3kd cell lines (B). Representative graphs of two to three experiments are shown. (C) Aβ levels in guanidine-extracted fraction in APP mice after LA-1 treatment. n = 8–9 mice, male and female. CX cortex, HC hippocampus. (D) Mass spectrometry quantification of brain levels of LA-1 after single injection. n = 3 per time point, all male mice. (E and F) qPCR analysis of mRNA from primary microglia. n = 5 individual mice, male and female. The dashed line shows the detection limit. (C–F) All mice were 3–4 mo old. One-way ANOVA and Tukey’s posthoc test (A), two-way ANOVA and Bonferroni posthoc test (B), or unpaired Student’s t test (C, E, and F) was used. *, P < 0.05; **, P < 0.01; ***, P < 0.001. All values are mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 5. LA-1 treatment decreases ISF Aβ concentration by enhancing clearance. (A) Time course of in vivo microdialysis. 8 h of baseline measurements, followed by LA-1 infusion for 16 h, and the last 4 h with additional infusion of Compound E. (B) Quantification of ISF Aβ concentrations after 6 h of LA-1 infusion. (C) Quantification of Aβ half-life. (D) Time course of in vivo microdialysis. 8-h baseline measurements, followed by 4-h LA-1 infusion and 12-h washout. (E) Quantification of D. (F) Time course of in vivo microdialysis in APP and APP/CR3−/− mice with 8 h of baseline, followed by 12 h of LA-1 infusion. (G) Quantification of ISF Aβ concentration after 6 h of LA-1 infusion. n = 5 mice per group, male and female (A–C); n = 2 mice, all male (D and E); or APP, n = 2 and APP/CR3−/−, n = 5, male and female (F and G). Unpaired Student’s t test was used. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. All values are mean ± SEM.
Figure 5. LA-1 treatment decreases ISF Aβ concentration by enhancing clearance. (A) Time course of in vivo microdialysis. 8 h of baseline measurements, followed by LA-1 infusion for 16 h, and the last 4 h with additional infusion of Compound E. (B) Quantification of ISF Aβ concentrations after 6 h of LA-1 infusion. (C) Quantification of Aβ half-life. (D) Time course of in vivo microdialysis. 8-h baseline measurements, followed by 4-h LA-1 infusion and 12-h washout. (E) Quantification of D. (F) Time course of in vivo microdialysis in APP and APP/CR3−/− mice with 8 h of baseline, followed by 12 h of LA-1 infusion. (G) Quantification of ISF Aβ concentration after 6 h of LA-1 infusion. n = 5 mice per group, male and female (A–C); n = 2 mice, all male (D and E); or APP, n = 2 and APP/CR3−/−, n = 5, male and female (F and G). Unpaired Student’s t test was used. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. All values are mean ± SEM.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

Items 101–135 of 135

Metadata

Authors
Czirr, E., Castello, N. A., Mosher, K. I., Castellano, J. M., Hinkson, I. V., Lucin, K. M., Baeza-Raja, B., Ryu, J. K., Li, L., Farina, S. N., Belichenko, N. P., Longo, F. M., Akassoglou, K., Britschgi, M., Cirrito, J. R., & Wyss-Coray, T.
Affiliations
  • Stanford Medicine (US)
  • University of California, San Francisco (US)
  • VA Palo Alto Health Care System (US)
  • Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305 1
  • Washington University in St. Louis (US)
Venue
Journal of Experimental Medicine
Published
2017-03-15
Volume
214
Issue
4
Pages
1081-1092
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2596986005
Cited by
126
References
71
Citations by year
2026: 5 · 2025: 12 · 2024: 26 · 2023: 20 · 2022: 9 · 2021: 16 · 2020: 17 · 2019: 9 · 2018: 7 · 2017: 5
FWCI
7.69
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
Funders
  • Alexander von Humboldt Foundation
  • Jane Coffin Childs Memorial Fund for Medical Research
  • National Institute of Neurological Disorders and Stroke (P01 NS074969)
  • National Institutes of Health
  • National Institute on Aging (R01 AG042513, AG045034)
  • Department of Veterans Affairs
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
Keywords
microglia, complement receptor 3, CD11b/CD18, Alzheimer's disease, amyloid clearance, tissue plasminogen activator, proteolytic activity, amyloid precursor protein transgenic mice, brain interstitial fluid, complement system, small molecule modulators, therapeutic target
MeSH terms
Alzheimer Disease, Animals, Benzoates, Brain, Mice, Inbred C57BL, Thiohydantoins, Macrophage-1 Antigen, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Mice, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.